Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504423 | 0.91 | CETP (0.37) | HSD11B1TRPM8CETPPTGS2SLC6A2 | |
| SCHEMBL4505876 | 0.90 | CETP (0.40) | HSD11B1TOP2ATOP2BTRPM8CETP | |
| SCHEMBL4501365 | 0.89 | MAOB (0.37) | HSD11B1TOP2ATOP2BGCGRKDM4E | |
| SCHEMBL4500724 | 0.88 | CETP (0.33) | HSD11B1CETPGCGRKDM4E | |
| SCHEMBL4504805 | 0.84 | HSD11B1 (0.34) | HSD11B1TRPM8PTGS2SLC6A2SLC6A4 | |
| SCHEMBL4519034 | 0.83 | CETP (0.39) | HSD11B1TOP2ATOP2BTRPM8CETP | |
| SCHEMBL4496503 | 0.83 | CETP (0.39) | HSD11B1TOP2ATOP2BTRPM8CETP | |
| SCHEMBL4496498 | 0.83 | CETP (0.39) | HSD11B1TOP2ATOP2BTRPM8CETP | |
| SCHEMBL4501298 | 0.81 | TOP2A (0.39) | HSD11B1TOP2ATOP2BKDM4EALDH1A1 | |
| SCHEMBL4507210 | 0.80 | CETP (0.46) | HSD11B1TRPM8CETPPTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-1999123-A1 | SUBSTITUTED CHROMANOL DERIVATIVES AND THEIR USE | Bayer HealthCare AG (DE) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107243-A1 | SUBSTITUTED CHROMANOL DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107243-A1 | SUBSTITUTED CHROMANOL DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | CYP46A1, CBX3, CDYL | HSD11B1 33/4885TOP2A 1310/4885TOP2B 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.